Angiotensin receptor blockers

Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers

Top

Kalaitzidis R, Bakris G. Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers. Diabetes, Obesity and Metabolism. 2009;11(8):757-769. Hypertension is an important cardiovascular (CV) risk factor in patients with diabetes mellitus. In this setting, tight control of blood pressure (BP) significantly reduces CV morbidity and mortality.

Prevention of diabetes & cardiovascular disease in patients w/ impaired glucose tolerance: rationale & design of Nateglinide & Valsartan

Top

Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR; NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J. 2008;156(4):623-632. Patients with impaired glucose tolerance (IGT) have increased risk for developing type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Lifestyle modification and medication can prevent or delay progression to diabetes (PD), but whether such interventions also reduce the risk of CVD has not been rigorously tested.

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease

Top

Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Arch Intern Med. 2008;148(1):30-48.

A managed care organization's use of integrated health management to improve secondary prevention of coronary artery disease

Top

Berthiaume JT, Davis J, Taira DA, Thein KK. A managed care organization's use of integrated health management to improve secondary prevention of coronary artery disease. Am J Manag Care. 2007;13(3):142-7. OBJECTIVE: To evaluate the effect of a managed care organization's multifactorial intervention program in optimizing secondary prevention of coronary artery disease (CAD).

Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension

Top

Park H, Hasegawa G, Obayashi H, et al. Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension. Clin Chimica Acta.. 2006;374:129-134. It is now well established that vascular inflammation and endothelial dysfunction associated with cardiovascular diseases contributes to insulin resistance. We investigated the relationship between the homeostasis model assessment-insulin resistance index and various serum inflammatory markers and the effect of losartan on serum concentrations of these markers in patients with type 2 diabetes and hypertension.

Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome

Top

Bakris G, Molitch M, Hewkin A, et al, for the STAR Investigators. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006;29:2592-2597. We sought to test the hypothesis that a fixed-dose combination of trandolapril/verapamil-SR is superior to a fixed-dose combination of losartan/hydrochlorothiazide on glucose tolerance in hypertensive patients with impaired glucose tolerance.

Effects of blood pressure lowering and metabolic control on systolic left ventricular function in Type II diabetes mellitus

Top

Andersen NH, Poulsen SH, Poulsen PL, et al. Effects of blood pressure lowering and metabolic control on systolic left ventricular function in Type II diabetes mellitus. Clin Sci (Lond). 2006;111:53-59. Decreased left ventricular long-axis function may be the earliest stage in subclinical heart failure in Type II diabetes.

Does albuminuria predict cardiovascular outcomes on treatment w losartan vs atenolol in patients w diabetes, hypertension & left ventricular hypertrophy?

Top

Ibsen H, Olsen MH, Wachtell K, et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care. 2006;29:595-600. OBJECTIVE: Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events.

Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes

Top

Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis. 2005;46:1080-1087. National guidelines recommend angiotensin-converting enzyme (ACE)-inhibitor or angiotensin receptor blocker (ARB) therapy in patients with diabetes who also have hypertension and/or proteinuria to retard the progression of renal damage. However, little is known about the adequacy of adherence to these guidelines in elderly patients with diabetes and predictors of such appropriate ACE-inhibitor or ARB use.

For those intolerant to ACE inhibitors and ARBs, what is the best therapy for reducing the risk of diabetic nephropathy?

Top

Penmetsa S, Simmons M, Daugird A. For those intolerant to ACE inhibitors and ARBs, what is the best therapy for reducing the risk of diabetic nephropathy? J Fam Pract. 2005;54:711-713. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) are the first-line agents for reducing the risk of diabetic nephropathy.

1 2 Next